Clinical Trial Update: Safety, Toleration and Efficacy of Single Inhaled Doses of PF-00610355 in Chronic Obstructive Pulmonary (COPD) Patients. [Phase 2]

View source ↗

Summary

A Phase 2 study assessing the safety, tolerability, and preliminary efficacy of single inhaled doses of PF-00610355 in adults with chronic obstructive pulmonary…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Obstructive Pulmonary Disease

Drugs mentioned

• PF-00610355

Snippet

Sponsor: Pfizer | Conditions: Pulmonary Disease, Chronic Obstructive | Phase 2 | Status: COMPLETED